DEA Telehealth Prescribing Rules for 2026: What PMHNPs Running a Practice Need to Know

For new and early-career PMHNPs navigating DEA telehealth rules PMHNP, here is what matters now:

The DEA just gave telehealth prescribers another year. Most PMHNPs celebrated. The smart ones started preparing.

On December 31, 2025, the DEA and HHS jointly announced a fourth temporary extension of COVID-era telemedicine flexibilities — the rules that allow practitioners to prescribe Schedule II through V controlled substances via telehealth without ever meeting a patient in person. The extension runs through December 31, 2026.

For PMHNPs who’ve built telehealth practices prescribing stimulants, benzodiazepines, and other controlled substances remotely, this extension is a lifeline. But it’s also a countdown. Permanent regulations are coming — and they won’t be as permissive as what we have now. The question isn’t whether the rules will change. It’s whether your practice will be ready when they do.

What the DEA Actually Extended (and What It Didn’t)

The extension preserves the full set of telemedicine flexibilities that were in place during the COVID-19 public health emergency. In practice, this means three things for PMHNPs:

Schedule II-V prescribing via audio-video. DEA-registered practitioners can prescribe stimulants (Adderall, Vyvanse, Concerta), benzodiazepines, and other Schedule II-V medications through video telehealth without requiring an initial in-person visit. This is the flexibility that made telehealth psychiatry viable for millions of patients — and it stays intact through 2026.

OUD treatment via audio-only. For Schedule III-V medications approved for opioid use disorder maintenance and withdrawal management (primarily buprenorphine products), practitioners can prescribe via audio-only encounters. This is critical for reaching patients in rural and underserved areas without reliable internet.

No Special Registration required — yet. Under the current extension, your existing DEA registration is sufficient. But the proposed permanent rules include a Special Registration for Telemedicine that would create a separate registration pathway specifically for telehealth prescribing. That’s the change PMHNPs need to watch.

What the extension did not change: the requirement that prescriptions serve a legitimate medical purpose, that practitioners hold valid state licenses, and that all applicable state laws still apply. Federal flexibility doesn’t override state restrictions.

“This extension isn’t permission to relax — it’s a runway. PMHNPs who use 2026 to tighten their documentation and build hybrid workflows will be the ones who thrive when permanent rules hit. The ones who assume the flexibilities will last forever will be scrambling.”

— Lindsay Hill, DNP, PMHNP-BC

What This Means for PMHNPs Running Telehealth Practices

If you’re a PMHNP building a telehealth practice — or considering one — 2026 is simultaneously the best and most urgent year to do it.

The business case is straightforward: telehealth eliminates overhead associated with physical office space, extends geographic reach across state lines (where compact licensure or state-specific licenses allow), and meets patients where they are. The mental health provider shortage means demand far exceeds supply in virtually every market. PMHNPs with telehealth practices are filling a gap that brick-and-mortar clinics can’t close fast enough.

The regulatory reality is more nuanced. The current flexibilities allow you to build a fully remote practice prescribing controlled substances to patients you’ve never met in person. That model works — until the permanent rules require an in-person evaluation for initial prescriptions of certain medications. If your entire practice is built on fully remote encounters, a regulation change could force you to restructure overnight.

The PMHNPs who will come out ahead are the ones who build hybrid-ready practices right now — practices that can flex between fully remote and hybrid models without breaking.

What Most PMHNPs Get Wrong About Telehealth Prescribing

The first misconception: federal telehealth rules override state requirements. They don’t. The DEA extension sets a federal floor, not a ceiling. Many states layer additional requirements on top — including collaborative agreements, state-specific PDMP protocols, and limitations on which controlled substances can be prescribed via telehealth. A PMHNP licensed in multiple states needs to track the rules for each one independently.

The second misconception: the extension means permanent rules will look the same. The DEA’s proposed permanent framework includes meaningful changes — most notably, the Special Registration for Telemedicine and potential requirements for in-person evaluations before initiating certain Schedule II prescriptions. Reading the current flexibility as a signal of future leniency is a strategic mistake.

The third misconception: documentation standards are lower for telehealth encounters. They’re not. In fact, telehealth prescribing of controlled substances requires additional documentation: patient identity verification, confirmation of patient location at time of service, PDMP check documentation, informed consent for telehealth, and clinical rationale for the chosen modality. Many PMHNPs are under-documenting and don’t realize it until an audit.

“The PMHNPs who get in trouble with telehealth prescribing aren’t the ones making bad clinical decisions — they’re the ones who can’t prove they made good ones. Documentation is what separates a defensible practice from a vulnerable one.”

— Lindsay Hill, DNP, PMHNP-BC

The Permanent Rules Are Coming — Here’s What to Expect

The DEA and HHS have signaled clearly: permanent regulations will be finalized before the December 2026 deadline. Based on the proposed rulemaking and public comments, here’s what PMHNPs should prepare for:

Special Registration for Telemedicine. The proposed framework would create a new DEA registration category specifically for practitioners who prescribe controlled substances via telehealth. This means a separate application process, potentially with additional requirements around training, technology standards, and compliance reporting.

Possible in-person requirements for initial Schedule II prescriptions. Early proposals suggested requiring an in-person evaluation before initiating stimulants and other Schedule II medications via telehealth. While the final rule may soften this requirement, PMHNPs should build workflows that can accommodate an initial face-to-face if needed.

Enhanced PDMP documentation requirements. Expect stricter requirements around documenting PDMP checks — not just running them, but documenting the results and clinical decision-making based on PDMP data in the patient record.

Technology and identity verification standards. The permanent rules will likely specify minimum standards for telehealth platforms, including HIPAA-compliant video capabilities and patient identity verification protocols that go beyond what many PMHNPs currently use.

How to Build a Telehealth Practice That Survives the Rule Change

Whether you’re launching a telehealth practice or optimizing an existing one, here are five moves to make in 2026:

Audit your documentation today. Pull 10 random telehealth charts involving controlled substances and check: Is patient identity verified and documented? Is the patient’s location at time of service recorded? Is the PDMP check documented with results? Is the clinical rationale for telehealth (vs. in-person) noted? Is informed consent for telehealth on file? If you’re missing any of these, fix the workflow before an auditor finds it.

Build hybrid-ready workflows. Identify partners or clinic space where initial in-person evaluations could happen if required. This doesn’t mean you need a permanent office — a shared clinic space, collaborative arrangement with a primary care practice, or per-diem office rental gives you the flexibility to pivot without signing a lease.

Diversify beyond controlled substances. If your entire revenue depends on prescribing stimulants and benzodiazepines via telehealth, you’re building on the most vulnerable regulatory ground. Expand your practice to include therapy referral coordination, non-controlled medication management (SSRIs, SNRIs, mood stabilizers), and comprehensive psychiatric evaluations that generate revenue independent of controlled substance prescribing.

Track state-level rules independently. Build a compliance matrix for every state where you’re licensed. Federal rules set the minimum — states can and do add requirements. One missed state-specific regulation can shut down your practice in that state overnight.

Monitor the Federal Register. The permanent rule will be published there first. Sign up for DEA and HHS Federal Register alerts so you’re not learning about new requirements from social media two weeks after they’re finalized.

“The best time to build a regulation-proof telehealth practice was two years ago. The second best time is right now. Use 2026 to tighten everything — documentation, compliance, hybrid workflows — so that when the permanent rules drop, you’re already there.”

— Lindsay Hill, DNP, PMHNP-BC, founder of the Psych NP Fellowship

Frequently Asked Questions

This content is for educational purposes and does not constitute legal advice. Telehealth prescribing regulations vary by state and are subject to change. Always consult current DEA guidance, state boards of nursing, and legal counsel when establishing or modifying telehealth prescribing practices.